Samsung Biologics completes first commercial-scale engineering run for mRNA COVID-19 vaccine

By Lim Chang-won Posted : August 2, 2022, 13:04 Updated : August 2, 2022, 13:04

[Courtesy of Samsung Biologics]

SEOUL -- Samsung Biologics, a leading bio company affiliated with South Korea's largest Samsung Group, has completed the first commercial-scale engineering run for the substance production of mRNA COVID-19 vaccines in partnership with technology transfer from its American partner, GreenLight Biosciences.

GreenLight, a biotechnology company dedicated to making ribonucleic acid (RNA) products, forged a strategic partnership with Samsung Biologics in late 2021 on a contract manufacturing organization (CMO) that serves other companies to provide comprehensive services from development through manufacturing.

"This demonstrates a major achievement in our continuing goal to offer one-stop end-to-end mRNA production from drug substance to aseptic fill finish to commercial release, all from a single site," Samsung Biologics John Rim said in a statement on August 2.

Samsung Biologics has completed the expansion of its mRNA drug substance manufacturing suite at its production base in Songdo west of Seoul. The company said it is now fully equipped to provide end-to-end mRNA production.

GreenLight would be capable of supplying mRNA vaccine at a commercial scale, with its COVID booster vaccine clinical trial expected to start in 2022. 
"We are grateful for the help and support of Samsung in demonstrating that our small mRNA process can scale in a linear fashion to the industrial scale that will be needed to help satisfy the vaccine needs of humanitym"  said GreenLight CEO Andrey Zarur. 

A second engineering run will start in August, to implement improvements indicated by the first run and to demonstrate repeatability at scale.
기사 이미지 확대 보기